News | October 17, 2023
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Ayush Minister launched month long ayurveda celebration drive of Ministry of Ayush
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Dozee Pro Ex will offer Ambulatory patient monitoring for a seamless continuum of patient monitoring across different care settings
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
